Lifesci Capital Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to “Strong-Buy”

Posted by Stanley Muller on Sep 30th, 2026

Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) was upgraded by equities research analysts at Lifesci Capital to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks reports.

Other equities analysts have also issued research reports about the stock. HC Wainwright reiterated a “buy” rating and set a $145.00 price objective on shares of Bright Minds Biosciences in a report on Wednesday, August 19th. Wall Street Zen upgraded Bright Minds Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Benchmark restated a “buy” rating on shares of Bright Minds Biosciences in a research note on Thursday, August 20th. BTIG Research restated a “buy” rating and set a $147.00 price objective on shares of Bright Minds Biosciences in a report on Monday, August 17th. Finally, Oppenheimer lowered Bright Minds Biosciences to a “market perform” rating in a report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Bright Minds Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $143.83.

Read Our Latest Report on DRUG

Bright Minds Biosciences Stock Performance

Shares of DRUG stock opened at $49.74 on Monday. Bright Minds Biosciences has a fifty-two week low of $48.94 and a fifty-two week high of $123.75. The stock has a 50 day simple moving average of $70.28 and a two-hundred day simple moving average of $74.10. The company has a market cap of $483.97 million, a P/E ratio of -23.91 and a beta of -5.36.

Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) last announced its quarterly earnings data on Monday, August 17th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($1.22) by $1.05. On average, research analysts predict that Bright Minds Biosciences will post -2.93 earnings per share for the current year.

Hedge Funds Weigh In On Bright Minds Biosciences

A number of large investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its position in Bright Minds Biosciences by 11.1% during the first quarter. Janus Henderson Group PLC now owns 1,284,324 shares of the company’s stock valued at $93,518,000 after buying an additional 128,329 shares during the period. Eventide Asset Management LLC bought a new stake in Bright Minds Biosciences in the 4th quarter worth $8,039,000. Vivo Capital LLC increased its position in shares of Bright Minds Biosciences by 11.1% in the first quarter. Vivo Capital LLC now owns 557,172 shares of the company’s stock valued at $40,657,000 after acquiring an additional 55,555 shares during the period. Orbimed Advisors LLC purchased a new stake in shares of Bright Minds Biosciences during the first quarter worth about $2,919,000. Finally, Artia Global Partners LP bought a new stake in shares of Bright Minds Biosciences in the fourth quarter worth about $2,607,000. Hedge funds and other institutional investors own 40.52% of the company’s stock.

About Bright Minds Biosciences

(Get Free Report)

Bright Minds Biosciences Inc is a biotechnology company focused on developing next-generation therapies for neuropsychiatric and neurological disorders. The company’s research centers on selective serotonin receptor agonists designed to address conditions such as treatment-resistant depression, substance use disorders and other disorders involving disrupted brain signaling.

Bright Minds’ lead program, BMB-101, is an orally administered, selective 5-HT2C receptor agonist being developed as a potential treatment for conditions including substance use disorder and related neuropsychiatric indications.